| 000 | 01557 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250513133816.0 | ||
| 264 | 0 | _c19980211 | |
| 008 | 199802s 0 0 eng d | ||
| 022 | _a0344-5704 | ||
| 024 | 7 |
_a10.1007/s002800050719 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAdedoyin, A | |
| 245 | 0 | 0 |
_aAll-trans-retinoic acid modulation of drug-metabolizing enzyme activities: investigation with selective metabolic drug probes. _h[electronic resource] |
| 260 |
_bCancer chemotherapy and pharmacology _c1998 |
||
| 300 |
_a133-9 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 |
_aAdenocarcinoma _xdrug therapy |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacokinetics |
| 650 | 0 | 4 | _aCytochrome P-450 Enzyme Inhibitors |
| 650 | 0 | 4 |
_aCytochrome P-450 Enzyme System _xmetabolism |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xblood |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMetabolic Clearance Rate |
| 650 | 0 | 4 | _aPhenotype |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aTretinoin _xpharmacokinetics |
| 700 | 1 | _aStiff, D D | |
| 700 | 1 | _aSmith, D C | |
| 700 | 1 | _aRomkes, M | |
| 700 | 1 | _aBahnson, R C | |
| 700 | 1 | _aDay, R | |
| 700 | 1 | _aHofacker, J | |
| 700 | 1 | _aBranch, R A | |
| 700 | 1 | _aTrump, D L | |
| 773 | 0 |
_tCancer chemotherapy and pharmacology _gvol. 41 _gno. 2 _gp. 133-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s002800050719 _zAvailable from publisher's website |
| 999 |
_c9412860 _d9412860 |
||